QNRX - Quoin Pharma targets regulatory nod for lead asset in 2024

Quoin Pharmaceuticals (NASDAQ:QNRX) plans to seek regulatory approval for its lead candidate QRX003 for Netherton Syndrome (NS) in 2024, the company’s Chief Operating Officer Denise Carter disclosed in an interview on Thursday. NS is a rare skin disorder without no approved therapy. It affects between 2,000 and 4,000 people in the U.S. and a similar number in Europe. The company has already submitted its Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) for QRX003 in NS. Having submitted a Scientific Advice Briefing Document to the European Medicines Agency (EMA) early this month, Quoin (QNRX) is currently waiting for regulatory guidance for its development in the European market. Plans are also underway in the U.S. to start a clinical trial for the candidate in H1 2022. Commenting on the prospects for commercialization of QRX003 for NS, Carter said that the company plans to launch the drug

For further details see:

Quoin Pharma targets regulatory nod for lead asset in 2024